Ekso Bionics to Exhibit Ekso GT Robotic Exoskeleton at AAPM&R and AMRPA Annual Meetings
Five Educational Sessions Featuring Robotic Rehabilitation
RICHMOND, Calif., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company, today announced that the company and its collaborators will exhibit their Ekso GT robotic exoskeleton in New Orleans at both the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly taking place October 20-23, 2016 and the American Medical Rehabilitation Providers Association (AMRPA) Annual Educational Conference taking place October 24-26, 2016.
Ekso Bionics will host a symposium in conjunction with AAPM&R on Friday, October 21 from 4:45 – 6:00 pm at the New Orleans Downtown Marriott Convention Center. During this symposium, Dr. Jeffrey Oken, Chief Medical Officer at Marianjoy Rehabilitation Hospital and Dr. Christina Kwasnica, Medical Director of Neuro-rehabilitation at Barrow Neurological Institute will discuss their research on the use of Ekso GT. In addition, Leslie VanHiel, DPT and Clinical Training Specialist at Ekso Bionics will review the most recent studies involving the Ekso GT device. A demonstration and Q&A will follow the symposium.
There are four educational sessions at AAPM&R dedicated to robotic therapy:
Session 401. Integrating Advanced Rehabilitation Technology and Robotics into Clinical Practice
7:30 AM–9:00 AM Oct 20, 2016; Convention Center, Meeting Room R08-09, Level 2
Erin Eggebrecht, PT, DPT, NCS
Deborah Gaebler-Spira, MD, McGaw Medical Center of Northwestern University (RIC) PM&R Program
Joshua Vova, MD
Session W204. Incorporating Exoskeletal Robots Into Practice
2:00 PM–3:30 PM Oct 20, 2016; Convention Center, Meeting Room 217, Level 2
Lauri Bishop, PT, DPT
Alberto Esquenazi, MD, Chmn Dept of PMR and Chief Med Off at Moss Rehab Hosp
Kristen Hohl, MD
Casey Kandilakis, PT, DPT, NCS
Donald Leslie, MD, Shepherd Ctr
Joel Stein, MD, Chair at Columbia Univ Med Ctr
Session 223. Frontiers in Rehabilitation Robotics
2:30 PM–4:00 PM Oct 22, 2016; Convention Center, Great Hall B, Level 1
Sunil Agrawal, PhD
Ethan Rand, MD, Assistant Professor at New York Prebyterian - Weill Cornell Medicine
Joel Stein, MD,Chair at Columbia Univ Med Ctr
Session 225. Robotics in Rehabilitation: Optimizing Treatment Delivery
4:15 PM–5:45 PM Oct 22, 2016; Convention Center, Great Hall B, Level 1
Alberto Esquenazi, MD, Chmn Dept of PMR and Chief Med Off at Moss Rehab Hosp
Matthew Vnenchak, PT
The following educational session will be offered at AMRPA:
Robotics in Neurorehabilitation: A Way to Improve Care Intensity and Efficiency
4:50 PM-5:50 PM Oct. 24, 2016; Royal Sonesta Hotel, Royal Conti Room
Alberto Esquenazi, MD, Chmn Dept of PMR and Chief Med Off at Moss Rehab Hosp
Ekso Bionics will be exhibiting at booth numbers 201 for AAPM&R and 18 for AMRPA.
About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
About Ekso™ GT
Ekso™ GT is the first FDA cleared exoskeleton cleared for use with stroke and spinal cord injuries from L5 to C7. The Ekso GT with smart Variable Assist™ (marketed as SmartAssist outside the U.S.) software is the only exoskeleton available for rehabilitation institutions that can provide adaptive amounts of power to either side of the patient’s body, challenging the patient as they progress through their continuum of care. The suit’s patented technology provides the ability to mobilize patients earlier, more frequently and with a greater number of high intensity steps. To date, this device has helped patients take more than 55 million steps in over 120 rehabilitation institutions around the world.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.
Media Contact: Carrie Yamond/Rajni Dhanjani 212-867-1788 cyamond@lazarpartners.com Investor Contact: Debbie Kaster 415-937-5403 investors@eksobionics.com
Released October 18, 2016